These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29658364)

  • 1. Prognostic value of PIVKA-II in hepatocellular carcinoma patients receiving curative ablation: A systematic review and meta-analysis.
    Zhang D; Liu Z; Yin X; Qi X; Lu B; Liu Y; Hou J
    Int J Biol Markers; 2018 Aug; 33(3):266-274. PubMed ID: 29658364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data.
    Yu R; Tan Z; Xiang X; Dan Y; Deng G
    BMC Cancer; 2017 Sep; 17(1):608. PubMed ID: 28863782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated PIVKA-II is associated with early recurrence and poor prognosis in BCLC 0-A hepatocellular carcinomas.
    Wang BL; Tan QW; Gao XH; Wu J; Guo W
    Asian Pac J Cancer Prev; 2014; 15(16):6673-8. PubMed ID: 25169507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of AFP and PIVKA-II responses for monitoring treatment outcomes and predicting prognosis in patients with hepatocellular carcinoma.
    Park H; Park JY
    Biomed Res Int; 2013; 2013():310427. PubMed ID: 24455683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.
    Svobodova S; Karlikova M; Topolcan O; Pecen L; Pestova M; Kott O; Treska V; Slouka D; Kucera R
    In Vivo; 2018; 32(6):1551-1554. PubMed ID: 30348715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NX-PVKA levels before and after hepatectomy of hepatocellular carcinoma as predictors of patient survival: a preliminary evaluation of an improved assay for PIVKA-II.
    Nanashima A; Abo T; Taura N; Shibata H; Ichikawa T; Takagi K; Arai J; Oyama S; Nagayasu T
    Anticancer Res; 2013 Jun; 33(6):2689-97. PubMed ID: 23749928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PIVKA-II is the best prognostic predictor in patients with hepatocellular carcinoma after radiofrequency ablation therapy.
    Takahashi S; Kudo M; Chung H; Inoue T; Ishikawa E; Kitai S; Tatsumi C; Ueda T; Nagai T; Minami Y; Ueshima K
    Oncology; 2008; 75 Suppl 1():91-8. PubMed ID: 19092277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
    Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
    J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
    Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
    Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
    Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
    World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and evaluation of analytical performance of a fully automated chemiluminescent immunoassay for protein induced by vitamin K absence or antagonist II.
    Fujita K; Kinukawa H; Ohno K; Ito Y; Saegusa H; Yoshimura T
    Clin Biochem; 2015 Dec; 48(18):1330-6. PubMed ID: 26210849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma.
    Hong YM; Cho M; Yoon KT; Chu CW; Yang KH; Park YM; Rhu JH
    Tumour Biol; 2017 Oct; 39(10):1010428317720863. PubMed ID: 29034775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein induced by vitamin K antagonist-II (PIVKA-II) is a reliable prognostic factor in small hepatocellular carcinoma.
    Kim JM; Hyuck C; Kwon D; Joh JW; Lee JH; Paik SW; Park CK
    World J Surg; 2013 Jun; 37(6):1371-8. PubMed ID: 23443153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
    Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
    Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Des-gamma-carboxy prothrombin in hepatocellular cancer patients waiting for liver transplant: a systematic review and meta-analysis.
    Lai Q; Iesari S; Levi Sandri GB; Lerut J
    Int J Biol Markers; 2017 Oct; 32(4):e370-e374. PubMed ID: 28561879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
    Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
    Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S; Rhim H; Kim YS; Kang TW; Song KD
    Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified CLIP using PIVKA-II for evaluating prognosis after hepatectomy for hepatocellular carcinoma.
    Nanashima A; Morino S; Yamaguchi H; Tanaka K; Shibasaki S; Tsuji T; Hidaka S; Sawai T; Yasutake T; Nakagoe T
    Eur J Surg Oncol; 2003 Nov; 29(9):735-42. PubMed ID: 14602492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
    Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
    Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.